Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

Next Previous
Trial Profile

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms EASE LID 3
  • Sponsors Adamas Pharmaceuticals

Most Recent Events

  • 26 Apr 2022 Results of pooled analysis from EASE LID, EASE LID 2 and EASE LID 3; valuating potential utility of Amantadine for persons with parkinson disease under consideration for device aided therapy, presented at the 74th Annual Meeting of the American Academy of Neurology 2022
  • 16 Sep 2021 According to an Adamas Pharmaceuticals media release, pooled data from GOCOVRI pivotal trials to evaluate efficacy of GOCOVRI as a first/early add-on treatment to levodopa for Parkinson's disease (PD) motor complications (OFF or dyskinesia) will be presented at the International Parkinson and Movement Disorder Society (MDS) 2021 .
  • 10 Jun 2021 Data from a post-hoc data analysis from two Phase 3 trials (EASE LID and EASE LID 3) were present in an Adamas Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top